fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Takeda has Completed its Acquisition of Shire

16/ 04/ 2019
  Takeda (Takeda Pharmaceutical Company Limited) announced the acquisition of Shire (Shire plc) at the beginning of the year. This step has accelerated the transformation of Takeda into a global, values-based, R&D-driven biopharmaceutical company that has expanded its geographic footprint and taken leading position in Japan and the U.S. Nowadays the company brings its highly-innovative medicines to patients in approximately 80 countries. Takeda’s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. The company also makes targeted R&D investments in Plasma-Derived Therapies (PDT) and Vaccines. Takedas strengthened highly-innovative R&D engine enables the company to develop a more global, robust and modality-diverse pipeline, as well as to focus on breakthrough innovation. The combined annual revenue of the company exceeds $30 billion USD. Christophe Weber, President and Chief Executive Officer of Takeda, says that integration of two companies into one is almost complete. The Operating Model, established in September 2018, has set a clear framework for Takeda’s integration plans. The company’s management team is confident that Takeda will retain its investment grade credit rating and will return to a net debt to EBITDA ratio of 2.0 within three to five years following completion.

Takeda (Takeda Pharmaceutical Company Limited) announced the acquisition of Shire (Shire plc) at the beginning of the year. This step has accelerated the transformation of Takeda into a global, values-based, R&D-driven biopharmaceutical company that has expanded its geographic footprint and taken leading position in Japan and the U.S.

Nowadays the company brings its highly-innovative medicines to patients in approximately 80 countries. Takeda’s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. The company also makes targeted R&D investments in Plasma-Derived Therapies (PDT) and Vaccines. Takeda’s strengthened highly-innovative R&D engine enables the company to develop a more global, robust and modality-diverse pipeline, as well as to focus on breakthrough innovation. The combined annual revenue of the company exceeds $30 billion USD.

Christophe Weber, President and Chief Executive Officer of Takeda, says that integration of two companies into one is almost complete. The Operating Model, established in September 2018, has set a clear framework for Takeda’s integration plans. The company’s management team is confident that Takeda will retain its investment grade credit rating and will return to a net debt to EBITDA ratio of 2.0 within three to five years following completion.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
0 Shares

Spelling error report

The following text will be sent to our editors: